Neurocrine Biosciences Financial Statements (NBIX)
|
|
|
|
Report date
|
|
|
07.02.2020 |
05.02.2021 |
11.02.2022 |
09.02.2023 |
09.02.2024 |
|
30.10.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
788.1 |
1 046 |
1 134 |
1 489 |
1 887 |
|
2 243 |
|
Operating Income, bln rub |
|
|
219.1 |
318.9 |
196.9 |
249.0 |
250.9 |
|
587.3 |
|
EBITDA, bln rub |
? |
|
226.6 |
336.1 |
218.7 |
264.6 |
416.1 |
|
619.5 |
|
Net profit, bln rub |
? |
|
37.0 |
407.3 |
89.6 |
154.5 |
249.7 |
|
385.9 |
|
|
OCF, bln rub |
? |
|
152.1 |
228.5 |
256.5 |
339.4 |
389.9 |
|
476.4 |
|
CAPEX, bln rub |
? |
|
14.7 |
10.9 |
23.4 |
16.5 |
28.3 |
|
36.3 |
|
FCF, bln rub |
? |
|
137.3 |
217.6 |
233.1 |
322.9 |
361.6 |
|
440.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
554.1 |
708.3 |
911.4 |
1 217 |
1 597 |
|
1 611 |
|
Cost of production, bln rub |
|
|
7.40 |
10.1 |
14.3 |
23.2 |
39.7 |
|
44.9 |
|
R&D, bln rub |
|
|
200.0 |
275.0 |
328.1 |
463.8 |
565.0 |
|
671.3 |
|
Interest expenses, bln rub |
|
|
32.0 |
32.8 |
25.8 |
7.10 |
4.60 |
|
2.20 |
|
|
Assets, bln rub |
|
|
1 306 |
1 735 |
2 073 |
2 369 |
3 251 |
|
3 535 |
|
Net Assets, bln rub |
? |
|
636.9 |
1 126 |
1 374 |
1 708 |
2 232 |
|
2 719 |
|
Debt, bln rub |
|
|
495.5 |
412.3 |
440.4 |
262.9 |
428.4 |
|
251.4 |
|
Cash, bln rub |
|
|
670.5 |
801.0 |
711.3 |
989.3 |
1 032 |
|
1 228 |
|
Net debt, bln rub |
|
|
-175.0 |
-388.7 |
-270.9 |
-726.4 |
-603.2 |
|
-976.6 |
|
|
Ordinary share price, rub |
|
|
107.5 |
95.9 |
85.2 |
119.4 |
131.8 |
|
113.4 |
|
Number of ordinary shares, mln |
|
|
91.6 |
93.1 |
94.6 |
95.8 |
97.7 |
|
101.1 |
|
|
Market cap, bln rub |
|
|
9 849 |
8 924 |
8 057 |
11 442 |
12 873 |
|
11 467 |
|
EV, bln rub |
? |
|
9 674 |
8 535 |
7 786 |
10 716 |
12 270 |
|
10 490 |
|
Book value, bln rub |
|
|
637 |
1 126 |
1 374 |
1 665 |
2 197 |
|
2 684 |
|
|
EPS, rub |
? |
|
0.40 |
4.37 |
0.95 |
1.61 |
2.56 |
|
3.82 |
|
FCF/share, rub |
|
|
1.50 |
2.34 |
2.46 |
3.37 |
3.70 |
|
4.35 |
|
BV/share, rub |
|
|
6.95 |
12.1 |
14.5 |
17.4 |
22.5 |
|
26.6 |
|
|
EBITDA margin, % |
? |
|
28.8% |
32.1% |
19.3% |
17.8% |
22.0% |
|
27.6% |
|
Net margin, % |
? |
|
4.69% |
38.9% |
7.90% |
10.4% |
13.2% |
|
17.2% |
|
FCF yield, % |
? |
|
1.39% |
2.44% |
2.89% |
2.82% |
2.81% |
|
3.84% |
|
ROE, % |
? |
|
5.81% |
36.2% |
6.52% |
9.05% |
11.2% |
|
14.2% |
|
ROA, % |
? |
|
2.83% |
23.5% |
4.32% |
6.52% |
7.68% |
|
10.9% |
|
|
P/E |
? |
|
266.2 |
21.9 |
89.9 |
74.1 |
51.6 |
|
29.7 |
|
P/FCF |
|
|
71.7 |
41.0 |
34.6 |
35.4 |
35.6 |
|
26.1 |
|
P/S |
? |
|
12.5 |
8.53 |
7.11 |
7.69 |
6.82 |
|
5.11 |
|
P/BV |
? |
|
15.5 |
7.92 |
5.86 |
6.87 |
5.86 |
|
4.27 |
|
EV/EBITDA |
? |
|
42.7 |
25.4 |
35.6 |
40.5 |
29.5 |
|
16.9 |
|
Debt/EBITDA |
|
|
-0.77 |
-1.16 |
-1.24 |
-2.75 |
-1.45 |
|
-1.58 |
|
|
R&D/CAPEX, % |
|
|
1 356% |
2 523% |
1 402% |
2 811% |
1 996% |
|
1 849% |
|
|
CAPEX/Revenue, % |
|
|
1.87% |
1.04% |
2.06% |
1.11% |
1.50% |
|
1.62% |
|
| Neurocrine Biosciences shareholders |
